Provided by Tiger Fintech (Singapore) Pte. Ltd.

CNS Pharmaceuticals, Inc.

3.12
+0.410015.13%
Post-market: 3.150.0300+0.96%19:56 EDT
Volume:354.12K
Turnover:1.08M
Market Cap:4.68M
PE:-0.02
High:3.35
Open:2.81
Low:2.73
Close:2.71
Loading ...

Company Profile

Company Name:
CNS Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
4
Office Location:
2100 West Loop South,Suite 900,Houston,Texas,United States
Zip Code:
77027
Fax:
- -
Introduction:
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Directors

Name
Position
Faith L. Charles
Director and Chairman of the Board
John M. Climaco
Chief Executive Officer and Director
Andrzej Andraczke
Director
Bettina Cockroft
Director
Carl Evans
Director
Jeffry R. Keyes
Director
Jerzy Gumulka
Director

Shareholders

Name
Position
John M. Climaco
Chief Executive Officer and Director
Christopher S. Downs
Chief Financial Officer
Donald Picker
Chief Science Officer
Sandra L. Silberman
Chief Medical Officer